|Bid||251.78 x 1100|
|Ask||260.25 x 900|
|Day's range||255.26 - 257.89|
|52-week range||212.40 - 317.17|
|Beta (5Y monthly)||1.03|
|PE ratio (TTM)||12.12|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||2.88 (1.13%)|
|Ex-dividend date||17 Aug 2022|
|1y target est||303.69|
Insiders who purchased US$933k worth of Laboratory Corporation of America Holdings ( NYSE:LH ) shares over the past...
Ladies and gentlemen, thank you for standing by, and welcome to the Labcorp Second quarter 2022 Earnings Call. With me today are Adam Schechter, chairman and chief executive officer; and Glenn Eisenberg, executive vice president and chief financial officer. This morning, in the investor relations section of our website at www.labcorp.com, we posted both a press release and an investor relations presentation with additional information on our business and operations, which includes a reconciliation of the non-GAAP financial measures to the GAAP financial measures discussed during today's call, as well as a presentation on additional information on the spin-off of the clinical development business.
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.